Clinical Trial Update: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates adding osimertinib to chemotherapy versus chemotherapy with placebo in non-small cell lung cancer, with results posted on 2026-01-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-13